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Background:We asked how partner subunits influence 6*-nicotinic receptor (nAChR) function.
Results:We found several, novel ways to manipulate effects of 5 subunits on 6*-nAChR function.
Conclusion: Extracellular domains in 6 and cytoplasmic/transmembrane domains in 6/3/5/3 subunits have unexpected
influences on 6*-nAChR function.
Significance: We found factors that influence assembly and function of 6*-nAChRs, which play important roles in mood,
reward, and nicotine dependence.
To further the understanding of functional 65*-nicotinic
acetylcholine receptors (nAChR; the asterisk (*) indicates
known or possible presence of other subunits), we have heter-
ologously expressed in oocytes different, mouse or human,
nAChR subunit combinations. Coexpression with wild-type 5
subunits or chimeric 5/3 subunits (in which the human 5
subunit N-terminal, extracellular domain is linked to the
remaining domains of the human 3 subunit) almost com-
pletely abolishes the very small amount of function seen for
64*-nAChR and does not induce function of 62*-nAChR.
Coexpression with human 5V9S subunits bearing a valine 290
to serine mutation in the 9 position of the second transmem-
brane domain does not rescue the function of 64*-nAChR or
induce function of 62*-nAChR. However, coexpression with
mutant chimeric 5/3V9S subunits has a gain-of-function
effect (higher functional expression and agonist sensitivity and
spontaneous opening inhibited by mecamylamine) on 64*-
nAChR. Moreover, N143D M145V mutations in the 6 sub-
unit N-terminal domain enable 5/3V9S subunits to have a
gain-of-function effect on 62*-nAChR. nAChR containing
chimeric 6/3 subunits plus either 2 or 4 subunits have
some function that is modulated in the presence of 5 or 5/3
subunits. Coexpression with 5/3V9S subunits has a gain-of-
function effect more pronounced than that in the presence of
5V9S subunits. Gain-of-function effects are dependent, some-
times subtly, on the nature and apparently the extracellular,
cytoplasmic, and/or transmembrane domain topology of part-
ner subunits. These studies yield insight into assembly of func-
tional65*-nAChR and provide tools for development of6*-
nAChR-selective ligands that could be important in the
treatment of nicotine dependence, and perhaps other neurolog-
ical diseases.
Nicotinic acetylcholine receptors (nAChR)3 exist as a variety
of subtypes composed from different combinations of geneti-
cally distinct subunits, with 2-7 and 2-4 subunits being
expressed in the nervous system (1). Some of these subunits
form homopentameric receptors when expressed in heterolo-
gous expression systems (7, 8, and 9), whereas other sub-
units assemble into heteropentameric structures with various
combinations of  and  subunits. Since its discovery in rat (2)
and chicken (3) brain as part of a gene cluster with nAChR 3
and 4 subunits, work on the 5 subunit has defined distribu-
tion of its mRNA, some of the effects of its incorporation on
properties of heterologously expressed nAChR, and how its
genetic elimination affects some behaviors (4–8). nAChR 5
subunits do not form functional receptors when expressed
alone nor in combinationwith any other single types of subunit,
but they are capable of integrating as accessory subunits into
complexes containing at least one other  and one other 
subunit (9–12).
nAChR 6 and 5 subunit messages share very similar
expression patterns, and some studies suggest that the 5 sub-
unit may participate in formation of functional 6*-nAChR
(where the asterisk (*) indicates the known or possible presence
of additional subunits in the complex), perhaps promoting
assembly and stability of mature 6*-nAChR (10, 13). Interest
in 65*-nAChR is increasing because 65*-nAChR, likely
expressed predominantly in dopaminergic midbrain regions
where they might modulate dopamine release, may be impli-
cated in pleasure, reward, and drug (including nicotine)
dependence, and could be involved in schizophrenia and Par-
kinson disease (6, 7, 14–16). 6*-nAChR that may exist in vivo
are not easily recreated in artificial expression systems (10). It
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has beendifficult to demonstrate the function of heterologously
expressed nAChR containing 6 and 5 subunits.
Recently Broadbent et al. (17) and we (18) observed that
incorporation of the human (h) nAChR 3 (h3) subunit has a
dominant-negative effect on the function of some heterolo-
gously expressed nAChR subtypes. By contrast, coexpression
with h3 subunits having a “reporter” mutation (valine 273 to
serine at the M2 second transmembrane domain 9 position,
h3V273S h3V9S) has a “gain-of-function” effect, potentiat-
ing the function of h6h2- or h6h4-nAChR (17), of nAChR
containing mouse (m) 6 subunits and h2 subunits, of
m6h4-nAChR, or of nAChR containing mutant h6
(h6N143DM145V) and h2 subunits (17, 18). Building on these
findings, we hypothesized that h5 subunits may also exert a
dominant-negative effect on h6h2- and h6h4-nAChR
function, in part because 5 and 3 subunits are phylogeneti-
cally similar, highly homologous, and share service as accessory
subunits in several nAChR subtypes. Acutely aware that coex-
pression with mutated h5 subunits (M2 second transmem-
brane domain 9 position, h5V290S  h5V9S) do not induce
spontaneous opening or increased agonist sensitivity of the
nAChR subtypes tested (19) we further hypothesized that
recombinant, chimeric h5/h3V273S subunits (in which the
N-terminal, large extracellular domain of the h5 subunit is
linked to the remaining domains of the gain-of-function
h3V9S subunit) would serve as a reporter mutation and, upon
integration into 6*-nAChR, would increase their agonist
sensitivity.
Here we report findings using a variety of wild-type, reporter
mutant, or chimeric nAChR subunits, hybrid nAChR contain-
ing subunits from different species, and the oocyte expression
system. We provide evidence that wild-type 5 or reporter
mutant h5V9S subunits are incorporated into complexes also
containing either h6 or m6 plus either h2 or h4 subunits,
but have a null or dominant-negative effect on the function of
those 6*-nAChR. We also show that chimeric h5/h3 sub-
units have similar effects, but that reporter mutant chimeric
h5/h3V9S subunits allow for agonist-activated and some
spontaneous function of h6h4*- or m6h4*-nAChR.
Moreover, we demonstrate that chimeric h6/h3 subunits
(10) expressed in combination with h2 or h4 subunits pro-
duce functional 6*-nAChR that are sensitive to dominant-
negative effects of coexpression with h5 or h5/h3 subunits,
but also become more sensitive to agonists and have much
higher function when coexpressed instead with h5V9S or chi-
meric, reporter mutant h5/h3V9S subunits. Finally we show
that mutations in the N-terminal domain of the h6 subunit
(N143D and M145V) enable (h5/h3V9S) subunits to have a
gain-of-function effect at h6h2*-nAChR. These findings
provide insight into the assembly, structure, and function of
functional 65*-nAChR, which could be exploited as models
for development of new ligands to affect mood and drug
dependence.
EXPERIMENTAL PROCEDURES
Chemicals—All chemicals for electrophysiology were ob-
tained from Sigma. Fresh nicotine and mecamylamine stock
solutions were made daily in Ringer solution and diluted as
needed.
nAChR Subunits: Mutants, Chimeras, and in Vitro
Transcription—cDNAs corresponding to human nAChR 6
(h6), h5, h2, h3, or h4 subunits were excised from vec-
tors containing them and subcloned into the oocyte expression
vector pGEMHE. Similarly, cDNA representing mouse nAChR
6 (m6) subunit (kind gift from Dr. Jerry A. Stitzel, Depart-
ment of Integrative Physiology, Institute for Behavioral Genet-
ics, University of Colorado, Boulder, CO) was subcloned into
pGEMHE. Construct integrity was confirmed by sequencing.
Point Mutants—Some specific mutations have been made in
residues present in the second transmembrane domain (M2) of
several nAChR subunits (e.g. at the so-called 9 or 13 positions,
counting residues starting at the presumed, first residue inM2).
Residues modified typically are thought to line the ion channel.
Many studies, for example (20), indicate that some of these
mutations can be used to monitor the incorporation of mutant
subunits into nAChR assemblies, because they sometimes pro-
duce incremental increases in agonist sensitivity (i.e. they lower
EC50 values for stimulation of nAChR function by a fixed
degree, which is proportional to the number ofmutant subunits
incorporated into the pentamer). Thus, these altered subunits
can serve as “reporter” mutants, because they can report when
and how many mutant subunits are present in a functional
nAChR. To the extent that they increase the apparent function
of the complex, typically by increasing the magnitude of the
peak whole cell current response to agonists relative to levels of
function seen in nAChR lacking those subunits or when wild-
type subunits are incorporated into complexes, but also by
increasing agonist sensitivity as described just above, they are
also called gain-of-function mutants. It is difficult to say
whether thesemutationsmight be physiologically relevant. The
M2 9 residue gain-of-function mutations in nAChR 7 sub-
units are lethal in transgenic mice (21), and to human, neuron-
like cell lines (22), and when present in a similar subunit, they
produce late-onset death in a subset of Caenorhabditis elegans
neurons (23). Thus, they may not be observed naturally in
mammals if they are embryonically lethal. However, these
mutations are very useful as experimental tools.
Gain-of-function/reporter mutations in h5 (V290S) or h3
(V273S) subunits were introduced into the pGEMHE back-
ground using the QuikChange II Site-directedMutagenesis Kit
(Stratagene, La Jolla, CA) and also confirmed. Similarly, muta-
tions in the N-terminal domain of the nAChR h6 subunit (i.e.
N143D  M145V) were introduced using the QuikChange II
Site-directed Mutagenesis Kit. Primers used for mutagenesis
are listed in Table 1.
(h5/h3) Subunit Chimera—To substitute the nAChR h5
subunit large, N-terminal, extracellular domain (E1) for the
equivalent segment of the h3 subunit cDNA, a cDNA corre-
sponding to amino acid residues 1 to 246 of h5 subunit cDNA
was first PCR-amplified using primers 5-taatacgactcac-
tataggg-3 (forward; T7: corresponding to the pGEMHE
sequence) and 5-ggcagcctccggattacaaatgag-3 (reverse; corre-
sponding to the nAChRh5 subunit sequence and containing a
BspEI site (underlined)). The PCR-amplified h5 subunit frag-
ment was subcloned into the pCR2.1-TOPO vector (Invitro-
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gen), in vivo amplified, and digested with BamHI and BspEI. A
BspEI restriction site (underlined) was created in the
pGEMHE-h3 construct by site-directed mutagenesis at posi-
tion Arg230 by using primers: 5- cacgtattccttcgtcctccggaggct-
gcctttattctatacc-3 (forward) and 5-ggtatagaataaaggcagcctccg-
gaggacgaaggaatacgtg-3 (reverse). The mutated pGEMHE-h3
plasmidwas digestedwith BamHI and BspEI, where the BamHI
site is located upstream of the N-terminal end of the h3 sub-
unit cDNAand in themultiple cloning site. The pGEMHEplas-
mid devoid of the h3 subunit N-terminal fragment was gel
purified. The restriction-digested h5 and pGEMHE-h3 frag-
ments were ligated, producing the chimera (h5/h3)
(h5(Met1-Ile246)/h3(Arg230-His458)) (Fig. 1), which includes
a total of 475 amino acid residues, and the final product was
checked for integrity by restriction enzyme analysis and DNA
sequencing prior to cRNA preparation.
h5/h3V9S Reporter Mutant Subunit Chimera—Similarly,
to create the h5/h3V9S subunit chimera containing a
reporter mutation, a BspEI restriction site was created in the
pGEMHE-h3V9S construct by site-directed mutagenesis at
positionArg230 using the same pair of primers as above, and the
rest of the procedures were the same as for creating the h5/
h3 subunit chimera. This resulted in a chimeric h5/h3V9S
subunit (h5(Met1-Ile246)/h3V273S(Arg230-His458)) (Fig. 1)
that includes a total of 475 amino acid residues andwas checked
for integrity by restriction enzyme analysis and DNA sequenc-
ing prior to cRNA preparation.
h6/h3 Subunit Chimera—The h6/h3 subunit chimera
plasmid ((containing the N-terminal, large extracellular
domain, E1) of the h6 subunit fused to domains from trans-
membrane region 1 through to the C terminus of the h3 sub-
unit) was a kind gift from Dr. John Lindstrom (10).
In Vitro Transcription—All pGEMHE plasmids were linear-
ized immediately downstream of the 3-polyadenylation
sequence. NheI was used to linearize m4, h6, h5, h5V9S,
h3, h3V9S, h5/h3, h5/h3V9S and h4 subunit-con-
taining plasmids. SbfI was used to linearize the h2 subunit
cDNA. The h6/h3 subunit chimera plasmid was linearized
using EcoRI. Capped mRNA was transcribed from linearized
plasmids in a reactionmixture (25l) containing 1 transcrip-
tion buffer, 1.6 mM rNTPs (Promega), 0.5 mM 7m-CAP (New
England Biolabs), 1 l of RNasin plus (New England Biolabs),
and 1l of T7RNApolymerase (NewEnglandBiolabs) with the
exception that the linearized h6/h3 subunit chimera was
transcribed using SP6 RNA polymerase (New England Biolabs)
following a standard protocol. Integrity and quality of the
cRNA was checked by electrophoresis and UV-spectroscopy.
Oocyte Preparation and cRNA Injection—Female Xenopus
laevis (Xenopus I, Ann Arbor, MI) were anesthetized using
0.2% tricaine methanesulfonate (MS-222). Ovarian lobes were
surgically removed from the frogs and placed in an incubation
solution that consisted of (in mM) 82.5 NaCl, 2.5 KCl, 1 MgCl2,
1 CaCl2, 1 Na2HPO4, 0.6 theophylline, 2.5 sodium pyruvate,
and 5 HEPES, plus 50 mg/ml of gentamycin, 50 units/ml of
penicillin, and 50 g/ml of streptomycin, pH 7.5. The frogs
were allowed to recover from surgery before being returned to
the incubation tank. The lobes were cut into small pieces and
digested with 0.08 Wunsch units/ml of liberase blendzyme 3
FIGURE 1. Schematic diagrams ofwild-type and chimeric human5 and3 subunits. The notations are:NN-terminal, large extracellular domain; I, II, III,
and IV are the four transmembrane domains; C-loop, second, large cytoplasmic loop; C, C terminus. The h51–246/h3230–458 chimera was constructed using a
BspEI restriction enzyme site engineered common to each subunit cDNA resulted in having a serine at position 231 instead of an arginine present in the
wild-type h3 subunit. The chimera was mutated back to have its wild-type amino acid arginine. The figure is not drawn to scale.
TABLE 1
Primers used in mutagenesis
For mutants, the first amino acid (single letter code) designates the wild-type residue at the numbered location (translation start methionine at position 1) that is replaced
with the second amino acid. Capitalized nucleotide(s) denote(s) those are different from the wild-type nAChR 6 subunit to create the designated replacement. F, forward
primer; R, reverse primer.
Mutant Primer sequences (53 3)
h5(V290S)-F 5-gtctctgcacttcagtacttTCgtctttgactgtcttccttc-3
h5(V290S)-R 5-gaaggaagacagtcaaagacGAaagtactgaagtgcagagac-3
h3(V273S)-F 5-cattatccacatcggTCttggtttctctgacagttttcc-3
h3(V273S)-R 5-ggaaaactgtcagagaaaccaaGAccgatgtggataatg-3
h6(N143DM145V)-F 5-ggcaaaacaaaagctcttcttaaatacGatggcGtgataacctggactccaccagctattt-3
h6(N143DM145V)-R 5-aaatagctggtggagtccaggttatcaCgccatCgtatttaagaagagcttttgttttgcc-3
Modulation of6*-Nicotinic Receptor Function:5 Subunits
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(Roche Applied Science) with constant stirring at room tem-
perature for 1.5–2 h. The dispersed oocytes were thoroughly
rinsed with incubation solution. Stage VI oocytes were selected
and incubated at 16 °C before injection. Micropipettes used for
injection were pulled from borosilicate glass (Drummond Sci-
entific, Broomall, PA) using a Sutter P87 horizontal puller, and
the tips were broken with forceps to 40 m in diameter.
cRNA was drawn up into the micropipette and injected into
oocytes using a Nanoject microinjection system (Drummond
Scientific) at a total volume of 60 nl. To express nAChR in
oocytes, about 4 ng of cRNA corresponding to each nAChR
subunit was injected. Lacking a priori knowledge about levels of
mRNA for specific subunits present in neurons, and not wish-
ing to bias results by injecting disparate amounts of nAChR
subunit cRNAs into oocytes, we chose to introduce identical
amounts of cRNA, presumably producing equal amounts of
each subunit protein, into oocytes. For several reasons as
explained under “Discussion,” we did not define subunit ratios
in the cell surface, functional nAChR in oocytes. Instead, we
provisionally assumed that 6 and 2 or 4 subunits would
form complexes having 2:3 and/or 3:2 ratios of the indicated
subunits and that oocytes also injected with 5 or 3 subunits
or variants would express nAChR with 2:2:1 ratios of 6:2 or
4:5 or 3 subunits.
Oocyte Electrophysiology—Two to 7 days after injection,
oocytes were placed in a small volume chamber and continu-
ously perfused with oocyte Ringer solution, which consisted of
(inmM) 92.5 NaCl, 2.5 KCl, 1 CaCl2, 1MgCl2, and 5HEPES, pH
7.5. The chamberwas grounded through an agarose bridge. The
oocytes were voltage-clamped at 70 mV (unless otherwise
noted) to measure agonist-induced currents using AxoClamp
900A and pClamp 10.2 software (Axon Instruments). The cur-
rent signal was low-pass filtered at 10 Hz with the built-in low-
pass Bessel filter in the Axoclamp 900A and digitized at 20 Hz
with Axon Digidata 1440A and pClamp 10.2. Electrodes con-
tained 3 M KCl and had a resistance of 1–2 megohms. Drugs
(agonists and antagonists) were prepared daily in bath solution.
Drugs were applied using a Valvelink 8.2 perfusion system
(Automate Scientific, Berkeley, CA). All electrophysiological
measurements were conducted or checked in at least two
batches of oocytes.
Experimental Controls—Injection of water or empty vector
(used as two forms of negative controls) or of cRNA corre-
sponding to one subunit alone or pairwise combinations of
nAChR h5, h5V9S, (h5/h3), or (h5/h3V9S) subunits
with either an 6 subunit or 2 or 4 subunits (10–12 ng of
total cRNA) did not result in the expression of functional
nAChR. Current responses to 100 M nicotine were less than
5–10 nA (data not shown).
Data Analyses—Raw data were collected and processed in
part using pClamp 10.2 (Molecular Devices, Sunnyvale, CA)
and a spreadsheet (Excel, Microsoft, Bellevue,WA), using peak
current amplitudes (Imax) as measures of functional nAChR
expression and results were pooled across experiments
(mean  S.E. for data from at least three oocytes). In some
cases, mean peak current amplitudes in response to a single
concentration of an agonist were compared across different
subunit combinations. However, assessment of true Imax values
for different nAChR subunit combinations required evalua-
tions based on more complete concentration-response rela-
tionships, in which mean peak current amplitudes at specified
ligand concentrations were fit to the Hill equation or its vari-
ants using Prism 4 (GraphPad Software, SanDiego, CA). F-tests
(p  0.05 to define statistical significance) were carried out to
compare the best fit values of log molar EC50 values across
specific nAChR subunit combinations. There are limitations in
the ability to compare levels of functional nAChR expression,
even though we injected similar amounts of RNA for all con-
structs. This is because expression levels assessed as peak
current amplitudes are affected by batch-to-batch variations
in oocytes, time between cRNA injection and recording, and
subunit combination-specific parameters, such as channel
open probability (influenced by gating rate constants, rates
and extents of desensitization), single channel conductance,
subunit assembly efficiency, and efficiency of receptor traf-
ficking to the cell surface (19). Wemade no attempt to meas-
ure or control for subunit combination-specific effects, but
whenever preliminary studies revealed possible differences
in peak current amplitudes, findings were further confirmed
across different subunit combinations using the same batch
of oocytes and the same time between cRNA injection and
recording. Peak current amplitudes are shown from repre-
sentative traces in some figures presented below, pooled data
from limited sets of studies, and mean peak current ampli-
tudes across all studies for a given combination of subunits
as presented in the tables sometimes differ. However, when
we make statements about results comparing ligand poten-
cies and efficacies across subunit combinations, the observa-
tions are clear, significant, and in agreement whether for
pooled data or for results from smaller sets of studies (one-
way analyses of variance followed by Tukey’s multiple com-
parison tests).
RESULTS
Studies of Incorporation of Human nAChR5 Subunits into
h6h4*- orm6h4*-nAChR1
Human nAChR Chimeric 5/3V9S Subunits (but Not
Human Wild-type 5, 5V9S, or 5/3 subunits) Form Func-
tional Receptors When Coassembled with h6h4*- or
m6h4*-nAChR and Increase Agonist Sensitivity of Expressed
Receptors—In initial studies, coexpression of nAChR wild-type
h6 andh4 subunits producednicotinic responsesmanifest as
inward currents in only about 3–5% of injected oocytes. Func-
tional responses to 100 M ACh when present were very mod-
est (22  3 nA) (data not shown). It was difficult to obtain
measurable and reproducible responses to nicotine. Coexpres-
sion with presumed accessory, wild-type h5, mutant h5V9S
subunits, or chimeric h5/h3 subunits along with wild-type
h6 andh4 subunits did not produce any response to nicotine.
However, coexpression with chimeric mutant h5/h3V9S
subunits as accessory partners significantly increased nicotinic
responses to 10 M nicotine (225  31 nA), and nearly every
oocyte injected with nAChR h6, h4, and mutant h5/
h3V9S subunits expressed functional nAChR (Fig. 2, Table 2).
These results at least indicated that both h5/h3 and mutant
Modulation of6*-Nicotinic Receptor Function:5 Subunits
37908 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 44•NOVEMBER 4, 2011
 at ELSEV
IER BV
 on Septem
ber 19, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
FIGURE 2. Functional properties of 64*-nAChR. A, representative traces are shown for inward currents in oocytes held at 70 mV, responding to
applicationat the indicatedconcentrationsof nicotine (shownwith thedurationofdrugexposure asblackbars above the traces), andexpressing (i) nAChRh6,
h4, and h5/h3V9S subunits or (ii) nAChR m6, h4, and h5/h3V9S subunits. Calibration bars are for (i) 40 or (ii) 100 nA currents (vertical) or 10 s
(horizontal). Note the differences in inward current kinetics. B, results for these and other studies averaged across experiments were used to produce
concentration-response curves (ordinate, mean normalized current S.E.; abscissa, ligand concentration in logM) for inward current responses to nicotine as
indicated, where current amplitudes are represented as a fraction of the peak inward current amplitude in response to the most efficacious concentration of
nicotine (h6h4(h5/h3V9S)-nAChR,; m6h4(5/3V9S)-nAChR,). Much higher levels of evoked currents are evident for functional nAChR contain-
ing h5/h3V9S subunits compared with receptors lacking or also containing altered forms of wild-type or chimeric 5 subunits, none of which gave
substantial or consistent currents responses (not shown; p 0.0001). See Table 2 for parameters.
Modulation of6*-Nicotinic Receptor Function:5 Subunits
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h5/h3V9S subunits incorporate into at least some complexes
containing h6 and h4 subunits, because agonist sensitivities
(EC50 values) that could be assessed changed as a function of
subunits injected into oocytes. Moreover, the results also
show that incorporation of nAChR h5/h3 subunits into
h6h4*-nAChR has a dominant-negative effect, reflected
by lack of functional receptors (again, assuming that peak
current amplitudes are legitimate proxies for functional
nAChR expression levels, with the caveats about this inter-
pretation mentioned under “Experimental Procedures,”
“Data Analyses”). By contrast, incorporation of nAChR h5/
h3V9S subunits produces a gain-of-function effect re-
flected by an increase in agonist sensitivity and in absolute
levels of functional receptor expression.
Knowing that at least some 6*-nAChR are functional in
mice, and but lacking such documentation of native, all-human
6*-nAChR function, we had previously extended our work to
mouse nAChR subunits and found that coexpression of h3
subunits with m6 and h4 nAChR subunits form hybrid (i.e.
composed of subunits from two different species), functional
m6h4h3-nAChR (18). This and the findings just above that
functional nAChR h6h4(h5/h3V9S) could be formed led
us to explore effects of the incorporation of h5 or h5/h3
subunits on function of the hybrid m6h4*-nAChR. Oocytes
expressing nAChR m6 and h4 alone or with wild-type h5
subunits from co-injected cRNAs failed to respond to nicotine
(Table 2). Substitution for wild-type h5 subunits with h5/
h3V9S subunits, but not with h5V9S or h5/h3 subunits,
yielded oocytes in which maximal responses were achieved in
the presence of 10 M nicotine (Fig. 2, Table 2). Nicotine con-
centration-response relationships yielded EC50 values of 0.87
M for m6h4(h5/h3V9S)-nAChR (Table 2). These find-
ings suggest that mutant h5/h3V9S subunits also serve as
gain-of-function partners for m6h4*-nAChR.
Human nAChR 5, 5V9S, 5/3, or 5/3V9S Subunits Do
Not Produce Functional Receptors When Coexpressed with h6
or m6 Plus h2 Subunits—Coexpression of nAChR wild-type
h6 orm6 plus h2 subunits did not yield oocytes responding
to nicotine (data not shown). Additional expression of wild-
type h5 or h5/h3 subunits does not alter this circumstance,
nor does additional expression of mutant h5V9S or h5/
h3V9S subunits (Table 2). These results indicate that although
the nAChR mutant h5/h3V9S subunits exert gain-of-func-
tion effects on h6h4*- or m6h4*-nAChR, they are unable
to activate the function of h6h2*- or m6h2*-nAChR
expressed in oocytes.
Studies of Human nAChR5 Subunit Incorporation into
Chimeric (h6/h3)*-nAChR
Coexpression of h5V9S or h5/h3V9S Subunits with Chi-
meric h6/h3 and h2 nAChR Subunits Produce Functional
TABLE 2
Parameters for ligand action at nAChR containing 6 nAChR subunits
Agonist potencies (micromolar EC50 values with 95% confidence intervals), Hill coefficients (nH SE), mean S.E. peak responses (Imax in nanoamps) and concentrations,
where Imax is achieved (M) are provided for nicotine acting at nAChR composed of the indicated subunits derived from the specified species and from the indicated number
of independent experiments (n) based on studies as shown in Figs. 2–5. For the indicated potency of the agonist or peak current responses when acting at the specified
nAChR subtype composed of the indicated subunits, significant (p 0.05) increases or decreases, respectively, are indicated relative to the 62- or 64-nAChR subtype
alone ( or ) or in the presence ofwild-type5 subunits (Œ or),5V9S subunits (‚ orƒ), or (5/3) subunits ( or ). Note that no or very rare and then small responses
to nicotine were seen for the following subunit combinations (n 4–9 each): h6 h2 alone or with h5, h5V9S, h5/h3, or h5/h3V9S; or h6 h4 alone or with
h5, h5V9S, or h5/h3; m6  h2 alone or with h5, h5V9S, h5/h3, or h5/h3V9S; m6  h4 a lone or with h5, h5V9S, or h5/h3; and
h6(N143DM145V) h2 alone or with h5, h5V9S, or h5/h3. No or very rare and then small responses were seen for the subunit combinations (n 6–9 each)
where data are entered as dashes.
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Receptors with Increased Sensitivity to Agonists—Oocytes
expressing chimeric h6/h3 and h2 subunits occasionally
displayed modest function that was reduced by coexpression
with h5 or h5/h3 subunits (Table 2). By contrast, nearly all
oocytes injected with h5V9S or h5/h3V9S subunit
cRNAs along with nAChR ha6/ha3 and h2 subunit cRNAs
yielded functional nicotinic responses (Fig. 3, Table 2).
Oocyte-expressed (h6/h3)h2(h5/h3V9S)-nAChR had
responses to nicotine at lower concentrations (0.03M EC50)
than seen for receptors containing h5/h3 subunits or no
5 subunit (13 M EC50), and there also was higher sensitiv-
ity to nicotine for (h6/h3)h2h5V9S-nAChR (1.1 M
EC50; Table 2). The findings for oocytes expressing h6/h3
and h2 subunits alone or with h5 subunits are consistent
with earlier observations by Kuryatov et al. (10). Interest-
ingly, Hill coefficients for agonist responses of (h6/
FIGURE 3. Functional properties of (h6/h3)h2*-nAChR.A, representative traces are shown for inward currents in oocytes held at70mV, responding to
application at the indicated concentrations of nicotine (shown with the duration of drug exposure as black bars above the traces), and expressing nAChR
h6/h3, h2, and either (i) h5V9S or (ii) h5/h3V9S subunits. Calibration bars are 100 (i) or 50 nA (ii) currents (vertical) or 10 s (horizontal). Note the
differences in inward current kinetics. B, results for these andother studies averaged across experimentswere used to produce concentration-response curves
(ordinate, mean normalized current  S.E.; abscissa, ligand concentration in log M) for responses to nicotine as indicated for oocytes expressing nAChR
h6/h3 andh2 subunits alone (f), with h5V9S subunits (F), orwith h5/h3V9S subunits (‚). Current amplitudes are represented as a fraction of the peak
inward current amplitude in response to themost efficacious concentration of nicotine. Leftward shifts in nicotine concentration-response curves are evident
for functional nAChR containing h5V9S or h5/h3V9S subunits (p 0.0001;12- and 433-fold lower EC50 values, respectively). See Table 2 for parameters.
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h3)h2(h5/h3V9S)-nAChR are shallow (nH  0.49) and
smaller than those for other functional (h6/h3)2*-
nAChR, perhaps suggesting heterogeneity or negative coop-
erativity in the complexes formed. Moreover, agonist EC50
values are 37-fold lower for (h6/h3)h2(h5/h3V9S)-
nAChR than for (h6/h3)h2(h5V9S)-nAChR.
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Coexpression of h5, h5V9S, h5/h3, or h5/h3V9S Sub-
units with Chimeric h6/h3 and h4 nAChR Subunits Pro-
duces Functional Receptors with Increased Sensitivity for
Agonists—Nearly all oocytes injected with h5, h5V9S, h5/
h3, or h5/h3V9S subunit cRNAs along with nAChR (h6/
h3) and h4 subunit cRNAs yielded functional nicotinic
responses (Table 2, Fig. 4). Oocytes expressing nAChR h6/
h3 and h4 subunits along with h5 subunits generally had
5-fold lower levels of function (although higher agonist sensi-
tivity; 9.1 M nicotine EC50 values) than oocytes expressing
nAChR h6/h3 and h4 subunits alone (25 M nicotine
EC50: Table 2). However, oocytes expressing nAChR h6/
h3 and h4 subunits along with h5/h3 subunits had
9-fold higher levels of function (also higher agonist sensi-
tivity; 6.1 M nicotine EC50 values) than oocytes expressing
nAChR h6/h3 and h4 subunits alone. By contrast, both
levels of functional receptor expression (3–13-fold higher
than for (h6/h3)h4-nAChR) and agonist sensitivity (2.9
and 0.03 M nicotine EC50 values, respectively; Fig. 4 and
Table 2) are increased when h6/h3 and h4 subunits are
FIGURE 4. Functional properties of (h6/h3)h4*-nAChR.A, representative traces are shown for inward currents in oocytes held at70mV, responding to
application at the indicated concentrations of nicotine (shown with the duration of drug exposure as black bars above the traces), and expressing nAChR
h6/h3, h4 and h5 (i), h5V9S (ii), h5/h3 (iii), or h5/h3V9S (iv) subunits. Calibration bars are for 20 (i), 200 (ii), 600 (iii), or 1000 nA (iv) currents (vertical)
or 10 s (horizontal). Note the differences in inward current kinetics. B, results for these and other studies averaged across experiments were used to produce
concentration-response curves (ordinate, mean normalized current S.E.; abscissa, ligand concentration in log M) for responses to nicotine as indicated for
oocytes expressing nAChR h6/h3 and h4 subunits alone (f), withwild-type h5 subunits (), h5V9S subunits (E), h5/h3 subunits (Œ), or h5/h3V9S
subunits (‚). Current amplitudes are represented as a fraction of the peak inward current amplitude in response to the most efficacious concentration of
nicotine. Leftward shifts in nicotine concentration-response curves are evident for functional nAChR containing h5, h5V9S, h5/h3, or h5/h3V9S
subunits (p 0.0001;3-,9-,3-, and 833-fold, respectively). See Table 2 for parameters.
FIGURE 5. Functional properties of h6(N143DM145V)h4*-nAChR. A, representative traces are shown for inward current responses in oocytes held at
70mV, responding to application of nicotine at the indicated concentrations (shownwith the duration of drug exposure as black bars above the traces), and
expressing nAChR h6(N143DM145V), h4, and (h5/h3V9S) subunits. Calibration bars are 40 nA current (vertical) or 10 s (horizontal). B, results for these
and other studies averaged across experiments were used to produce concentration-response curves (ordinate, mean normalized current  S.E.; abscissa,
ligand concentration in log M) for inward current responses to nicotine, where current amplitudes are represented as a fraction of the peak inward current
amplitude in response to the most efficacious concentration of nicotine. See Table 2 for parameters.
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expressed with h5V9S or h5/h3V9S subunits. The find-
ings for oocytes expressing h6/h3 and h4 subunits alone
or with h5 subunits are consistent with earlier observations
by Kuryatov et al. (10). Once again, Hill coefficients for ago-
nist responses of (h6/h3)h4*-nAChR were lower (nH 
0.49) in the presence of coexpressed h5/h3V9S subunits,
even in the presence of h5V9S subunits, and smaller than
those for other functional (h6/h3)2*-nAChR, a classic
indication of negative cooperativity but also possibly of het-
erogeneity in complexes formed. Moreover, agonist EC50 values
are 100-fold lower for (h6/h3)h4(h5/h3V9S)-nAChR
than for (h6/h3)h42(h5V9S)-nAChR.
Coexpression of h5/h3V9S Subunits with h6(N143D 
M145V) and h2 nAChR Subunits Produces Functional
Receptors—Earlier, we had shown (18) that mutations in the
N-terminal domain of the nAChR h6 subunit enable
nAChR h3V9S subunits to exert a gain-of-function effect at
h6(N143DM145V)h2*-nAChR (i.e. h6(N143D
M145V)h2h3V9S-nAChR are functional). This finding led
us to explore effects of incorporation of h5 or h5/h3 sub-
units into h6(N143DM145V)h2*-nAChR.
Oocytes injected with h5, h5V9S, or h5/h3 subunit
cRNAs alongwith nAChRh6(N143DM145V) and h2 sub-
unit cRNAs did not yield functional nicotinic responses
(Table 2). However, oocytes injected with h5/h3V9S sub-
unit cRNAs along with nAChR h6(N143DM145V) and
h2 subunit cRNAs yielded functional responses with an
EC50 value of 0.06 M for nicotine (Table 2, Fig. 5). The
maximal current response was 132  77 nA (mean  S.E.)
for 10 M nicotine.
Exposure to Mecamylamine Reveals Spontaneous Channel
Opening of nAChR Containing h5/h3V9S Subunits—Speci-
ficity of nicotine effects were routinely assessed based on the
ability of the noncompetitive nAChR antagonist, mecamyl-
amine, to block agonist-induced inward currents, but in doing
so, we observed reversal of currents at very high concentrations
of mecamylamine in the presence of nicotine. Effects of
mecamylamine alone were absent when assessed using oocytes
expressing any combination ofwild-type nAChR subunits (data
not shown). However, exposure to mecamylamine alone pro-
duced concentration-dependent, reversible, outward currents
in oocytes expressing h6 and h4 subunits in combination
with h5/h3V9S subunits but not with h5V9S subunits (Fig.
6, Table 3). These results suggest that there is spontaneous
opening of 6*-nAChR containing mutant h5/h3V9S sub-
units but not with h5V9S subunits, and that mecamylamine
mediates the open channel blockwith an IC50 value of 135Mat
these spontaneously opening h6h4(h5/h3V9S)-nAChR
(Fig. 6, Table 3). Amplitudes of the mecamylamine-induced
outward currents are about 66% of the amplitudes of agonist-
induced inward currents, suggesting that a substantial per-
centage (40%; maximum outward current of 150 nA
divided by the sum of that figure plus the maximum inward
current of 225 nA; Table 3; see Fig. 6) of h6h4*-nAChR
containing mutant h5/h3V9S subunits are spontaneously
open at any time.
As was the case for oocytes expressing h6, h4, andmutant
h5/h3V9S subunits or expressing m6, m4, and mutant
h5/h3V9S subunits, oocytes co-injected with cRNAs for
m6, h4, and h5/h3V9S subunits gave outward current
responses to mecamylamine in a concentration-dependent,
reversible manner (Fig. 6, Table 3). This inhibition of sponta-
neous channel opening occurred with an IC50 value of 50 M
mecamylamine. Estimates are that40% of these receptors are
spontaneously open at any one time.
Similarly, oocytes expressing (h6/h3)h2(h5/h3V9S)-
or (h6/h3)h4(h5/h3V9S)-nAChR gave outward current
responses to mecamylamine in a concentration-dependent,
reversible manner (Fig. 6, Table 3). This inhibition of sponta-
neously opening (h6/h3)h2(h5/h3V9S)- and (h6/
h3)h4(h5/h3V9S)-nAChR occurred with an IC50 value of
30 and 56 M, respectively. Estimates are that 19–20% of
these receptors are spontaneously open at any one time.
FIGURE 6. Functional properties of antagonist action at 6*-nAChR containing h5/h3V9S subunits. A, representative traces are shown for outward
currents in oocytes held at70mV, responding to application at the indicated concentrations of mecamylamine (shownwith the duration of drug exposure
as black bars above the traces), and expressing nAChR containing h6 and h4 (i), m6 and h4 (ii), h6/3 and h2 (iii), or h6/3 and h4 subunits (iv), all
along with h5/h3V9S subunits. Calibration bars are 50 (i and ii), 10 (iii), or 300 (iv) nA currents (vertical) or 10 s (horizontal). Note the differences in inward
current kinetics. B, results for these and other studies averaged across experiments were used to produce concentration-response curves (ordinate, mean
normalized current S.E.; abscissa, ligand concentration in log M) for outward current responses to mecamylamine as indicated, for h6h4(h5/h3V9S)-
(E), m6h4(h5/h3V9S)- (F), (h6/3)h2(h5/h3V9S)- (), or (h6/3)h4(h5/h3V9S)-nAChR (f), where current amplitudes are represented as a
fraction of the resting current amplitude. See Table 3 for parameters.
TABLE 3
Parameters for antagonist action at 6*-nAChR containing h5/h3V9S nAChR subunits
Inhibitor potencies (micromolar IC50 values with 95% confidence intervals), Hill coefficents (nH S.E.), mean S.E. peak responses (Imax in nanoamps), and concentrations
where Imax is achieved (M) are provided for mecamylamine acting at nAChR composed of the indicated subunits derived from the specified species and from the indicated
number of independent experiments (n) based on studies as shown in Fig. 6. Note that no or very rare and then small responses tomecamylaminewere seen for the following
subunit combinations (n 9 each): h6 h2with h5V9S or h5/h3V9S; h6 h4with h5V9S; m6 h2with h5V9S or h5/h3V9S; m6 h4with h5V9S;
h6/h3 h2 with h5V9S; and h6/h3 h4 with h5V9S.
Mecamylamine
Potency Peak response
nAChR subunit combinations n IC50 (95% CI) nH S.E. n Mean Imax S.E. Imax concentration
M nA M
h6 h4 h5/h3V9S 3 135 (23–779) 0.65 0.23 3 150 21 1000
m6 h4 h5/h3V9S 4 50 (20–125) 0.84 0.29 4 125 35 1000
h6/h3 h2 h5/h3V9S 3 30 (4.6–196) 0.86 0.45 3 67 22 1000
h6/h3 h4 h5/h3V9S 3 56 (40–78) 1.1 0.16 3 695 95 1000
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DISCUSSION
Although excellent studies have determined the distribution
of nAChR 5 subunit messages in the rodent brain, but left
largely uninvestigated is how 5 subunits might incorporate as
accessory partners into nAChR subtypes, specifically into 6*-
nAChR. To understand how 5 subunits might incorporate
into 6*-nAChR, we exploited the reporter or gain-of-function
mutant strategy (20) to reveal whether 5 subunits or their
variants integrate into 6*-nAChR complexes that are on the
cell surface and functional. This approach allows focus on cell
surface, functional receptors without complications due to
ambiguities of protein chemical or immunochemical studies
confounded by the prevalent expression of intracellular and
perhaps partially assembled receptor complexes, and the unre-
liable quality and/or availability ofmost anti-nAChR antibodies
for use in immunoprecipitation and/or immunoblot studies.
Furthermore, we used chimeric subunits and hybrid nAChR as
tools. In addition, we based the current studies on our findings
(18) that (i) incorporation of nAChR 3 subunits into 6*-
nAChRhas a dominant-negative effect that can be overcome by
introducing a gain-of-function mutation into a key residue in
the M2 second transmembrane domain of the 3 (or other)
subunit, (ii) incorporation of nAChR h3 subunits into
m6h4*-nAChR leads to formation of functional nAChR, and
(iii) mutations in the E1 N-terminal domain of the nAChR h6
subunit are essential for successful assembly and formation of
functional h6(N143DM145V)h2h3V9S-nAChR.
The principal observations of the current study are as follows.
Coexpression in Xenopus oocytes of nAChR h6 subunits, h4
subunits, and wild-type h5 subunits fails to produce functional
receptors (i.e. significant and reproducible, inward current
response to nicotine), eliminating the small amount of function
seen in some cases when oocytes express just h6 plus h4 sub-
units. No function is seen in the absence or presence of wild-type
h5 subunits in oocytes expressing h6 and h2 subunits. More-
over, no function is seen for hybrid (a mixture of subunits from
different species) m6h2*- or m6h4*-nAChR when those
subunits are coexpressed with h5V9S subunits or when 6 and
either 2 or 4 subunits are coexpressed with chimeric h5/h3
subunits.Bycontrast, there is veryclearevidence for incorporation
of chimeric,mutant h5/h3V9S subunits containing a valine 273
to serine mutation into 64*-nAChR, because oocytes express-
ing the indicated subunits have large, agonist-induced, peak
inward current responses.Moreover, agonist sensitivity of64*-
nAChR containing mutant h5/h3V9S subunits is higher than
for the equivalent receptors expressed in the absence of mutant
subunits. Chimeric h6/h3 subunits (10) form functional
nAChRwhen combinedwith either nAChR h2 or h4 subunits.
Further incorporation of h5 or h5/h3 subunits diminishes
functional responsiveness, but levels of functional expression and
sensitivity to nicotine are increasedwhenh6/h3 and either h2
or h4 subunits are coexpressed with h5V9S or h5/h3V9S
subunits. Interestingly, (h6/h3)2*- or (h6/h3)h4*-nAChR
complexes in oocytes coexpressing h5/h3V9S subunits have
higher agonist sensitivity than in the presence of coexpressed
h5V9S subunits. When there is expression of functional recep-
tors containing h5/h3V9S subunits, but not h5V9S subunits,
mecamylamineexposureproducesoutwardcurrents, indicativeof
spontaneouschannelopening in thepresenceofh5/h3V9S sub-
units, and that mecamylamine blocks spontaneously open chan-
nels and agonist-induced open channels. Finally, there is expres-
sion of functional receptors when h5/h3V9S subunits (but not
h5, h5V9S, or h5/h3 subunits) are coexpressed with
h6(N143DM145V) and h2 subunits.
We derive several conclusions from these findings. One is
that nAChR 5 subunits or their variants can incorporate into
heterologously expressed 64*-nAChR, where they exert
dominant-negative (wild-type h5 or h5/h3 subunits) or
gain-of-function (mutant h5/h3V9S subunits) effects. The
inability of wild-type, mutant, chimeric, or mutant chimeric 5
subunit variants to influence function of 62*-nAChR con-
founds the ability to make inferences about assembly of the
indicated subunits. However, we also conclude from studies
with h6(N143DM145V) subunits that the N-terminal
domain of 6 subunits influences the ability to see a mutant
5/3V9S subunit-mediated, gain-of-function effect at 62*-
nAChR, consistent with earlier findings that h3V9S subunits
have a gain-of-function effect when expressed as part of
h6(N143DM145V)h2h3V9S-nAChR. Effects of mecam-
ylamine are interpreted as demonstrating that 6*-nAChR that
show gain-of-function have a significant probability of sponta-
neous channel opening, consistent with the observation that
other receptors containing subunits with second transmem-
brane domain, gain-of-function mutations can open spontane-
ously in a way sensitive to open channel blockers (24, 25). Gain-
of-function effects found for the 5/3V9S mutant chimeric
subunit are largely similar to those found for 3V9S mutant
subunits, but in some cases yield functional receptors with dif-
ferent agonist sensitivities, suggesting subunit-specific subtle-
ties in coupling between ligand binding and channel opening.
The studies using nAChR containing chimeric 6/3 subunits
provide a more reliable functional background when expressed
as binary complexes with 2 or 4 subunits and underscore the
interpretation that wild-type 5 or chimeric 5/3 subunits
have a dominant-negative effect and that 5V9S, in addition to
5/3V9S subunits, exert gain-of-function effects. However,
magnitudes of nicotine-evoked currents, sensitivity to nicotine,
and the extent of spontaneous opening differ for receptors con-
taining5V9S or5/3V9S subunits, thus providing additional
evidence that fine features of subunits influence their effects on
6*-nAChR function. In the aggregate, althoughwe cannot dis-
count the possibility that inclusion of mutant subunits
increases the efficiency of incorporation of functional receptors
into the cell surface, we think that inclusion of these reporter
mutant subunits enhances the functional gain of receptors (20,
26) expressed at about the same level, in part as evident by
changes in agonist sensitivity, increases in peak inward current
magnitude, and increased susceptibility to spontaneous channel
opening. This lessens epistemological constraints on experiments
by allowing more ready detection of functional receptors, as do
studies of nAChR containing chimeric h6/h3 subunits.
The current findings are in general agreement with and extend
upon recent experimental successes demonstrating that nAChR
6 subunits, long refractory to heterologous expression (27, 28) in
functional nAChR assemblies with other subunits, indeed can
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interact with 2 or 4 subunits to form functional receptors in
oocytes.Thecurrent studieshaveovercomedifficulties in express-
ing and characterizing 65*-nAChR, in part by demonstrating
that (i) a dominant-negative effect of wild-type 5 subunits on
6*-nAChRcanbe counteracted using a gain-of-function strategy
and (ii) mutations in the N-terminal domain of 6 subunit are
essential for a gain-of-function effect at 62*-nAChR.
Recently, it was observed (17, 18) that incorporation of the
human nAChR 3 subunit has a dominant-negative effect on
the function of specific nAChR subtypes including h6h4*-
and h6h2*-nAChRheterologously expressed in oocytes. The
current findings extend upon these previous findings and rein-
force the perspective that3 and5 subunits are highly homol-
ogous and serve as auxiliary subunits in formation of functional
nAChR. Contrary to the gain-of-function observed for 3V9S
subunits, 5V9S subunits did not exert any gain-of-function in
combination with wild-type 6 and 2 or 4 subunits. However,
we have extended the work to show that gain-of-function occurs
for h5/h3V9S subunits. Moreover, wild-type 5 subunits show
a dominant-negative effect, and 5V9S subunits do exert a gain-
of-function effect when coexpressed with chimeric h6/h3 and
2 or 4 subunits, further reinforcing our interpretation.
Lack of or low level of function compromised our ability to
definitively generate EC50 values for agonists at h6h2h5-,
m6m2h5-, m6h2h5-, h6h4h5-, m6m4h5-,
m6h4h5-, (h6/h3)h2h5-nAChR, etc., but an EC50 value
of9.1Mnicotine for (h6/h3)h4h5-nAChR is fromour stud-
ies.NicotineEC50 valuesgenerated fromthecurrent study (0.03–2
M) for receptors containing (h5/h3V9S) subunits reflect the
increased agonist sensitivity of receptors harboring gain-of-func-
tion mutant subunits as has been seen for other nAChR subunits
mutated the same way at equivalent residues (20, 29).
One of the more interesting but mysterious observations is the
lack-of-function in oocytes expressing many combinations of 6
or even h6(N143DM145V) subunits plus 2 or 4 subunits in
the presence of h5V9S subunits when previous studies (17, 18)
demonstrated function of those combinations in the presence of
h3V9S subunits, even though 3 and 5 subunits are highly, but
not perfectly, homologous. The fact that function is expressed in
the presence of chimeric h5/h3V9S subunits suggests that fea-
tures in the3 subunit as opposed to in the5 subunitC-terminal
to E1 (including the second, large cytoplasmic loop and all four
transmembrane domains, but also containing a small cytoplasmic
loop between the first and second transmembrane domains, an
extracellular linker between the second and third transmembrane
domains, and the extracellular C-terminal tail) facilitate assembly
of functional complexes and thegain-of-functionbehaviorofh5/
h3V9S subunits. Studies of (h6/h3)h2*- or (h6/h3)h4*-
nAChR showing more evident dominant-negative effects of 5
subunits and gain-of-function effects of 5V9S subunits also sup-
port these suggestions. This is because domains C-terminal to E1
from the 3 subunit might be more compatible than those from
the 6 subunit with regard to productive assembly of functional
nAChR in combination with 5 subunits, overcoming possible
incompatibilities in those domains between 6 and 5 subunits.
Moreover, the potentiation of chimeric 5/3 subunits rather
than the dominant-negative influence of 5 subunits on function
of (h6/h3)4*-nAChR also is consistentwith heretofore unrec-
ognized roles of 5 or 3 domains C-terminal to E1 (and other
than an M2 9 mutation itself) in formation of functional 6*-
nAChR and agonist sensitivity.
Because there are indications that naturally expressed, rodent
62*-nAChR seem to be functional, perhaps when combined
with 5 subunits, and given the difficulties in heterologously
expressing human 62*-nAChR, we wondered whether there
simplymight be species-specific differences in the ability to heter-
ologously express625*-nAChR, and sowe chose to see ifm6
and h2 nAChR subunits could be functionally expressed when
combined with h5 subunits or their variants. However, we real-
ized very similar outcomes in our studies of all human, all mouse,
or hybrid 625*-nAChR, even when 5 or (5/3) subunits
hadgain-of-functionmutations anddespite success of the (5/3)
subunit gain-of-function strategywhen applied to64*-nAChR.
It ispossible that akeyassemblypartner, suchas4or3subunits,
are required for formation of naturally expressed, functional
625*-nAChR, and we are involved in studies to test this
hypothesis. Another possibility thatwould bemuchmore difficult
to test is that oocytes, but not the right kinds of nerve cells, lack
chaperones that facilitate assembly and functional expression of
625*-nAChR.
Someof our other site-directedmutagenesiswork implicated
6 residues 143 and 145 in the ability of 3 subunits to affect
62*-nAChR function (18). The h6(N143DM145V)muta-
tions change the indicated residues to those that are in them6
subunit and permits mutated h6 subunits to show function
when coexpressed with h2 and either h3V9S or h5/h3V9S
subunits when wild-type h6 subunit do not. This is very inter-
esting for two reasons. First, agonist binding domains are thought
to be present at the interface between E1 domains of specific
nAChR subunits, where the principal or () face is contributed by
one subunit via the so-calledA, B, andC loops, which are apposed
to the D, E, and F loops in the () or complementary face of the
neighboring subunit. The consensus perspective would predict
that the 6()/()2 or 6()/()4 subunit interfaces are
where therewouldbeproductive and functionally relevant agonist
binding. That is, they would be at the two 6:2 interfaces in a
complex with the arrangement, counterclockwise when viewed
from the extracellular space, of 3 (or 5):6:2:6:2. However,
6 residues 143 and145 are in theE1domain, in loopE, on the ()
or complementary face of the subunit. This means, unexpectedly,
thatmutations in the6subunit interface thoughtnot toengage in
agonist binding influences formation of functional receptors with
2 subunits and with subunits that contain either 3 or 5 E1
domainscoupled to3subunitdomainsC-terminal toE1 (inaddi-
tion to the reporter V293S mutation). This suggests that interac-
tionsbetween the6subunit () facewith the () face fromeither
2 subunits or from either 3 or 5 subunits are important for
functional 6*-nAChR expression, raising the question as to
whether agonists also bind at that interface to play allosteric or
co-agonist roles. At a finer detail level, onemight hypothesize that
the introduction of a negatively charged side chain at position 143,
amodest increase in hydrophobicity index (from 74 to 79) at resi-
due 145, and/or a difference in side chain volume at position 145
might enhance interactionsbetween6and2,3or5 subunits,
and the ability of ligands to bind at that interface. Second, because
the6 subunit () facemutations affect functionalnAChRforma-
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tionwith2 subunits andeitherh3V9S orh5/h3V9S subunits,
it does not seem that the 5()/()6 or 3()/()6 E1 inter-
faces are critical, but rather that the 2()/()6 E1 interface is
important. The analogous interface in 42-nAChR (2()/
()4) is an allosteric site of action of Zn2 (30).2:6E1 subunit
interfaces in the vicinity of loop E could play roles in subunit
assembly leading to closure of functional, cell-surface
623V9S-nAChR, although distal involvement of 2:6 sub-
unit interfaces in ligand binding or transduction of ligand binding
to channel gating cannot be discounted. The lack of function of
h6(N143DM145V)h2h5V9S-nAChR again is consistent
with limited compatibility between 6 and 5 subunit domains
C-terminal to E1.
In conclusion, our results provide evidence that wild-type or
mutant 5 subunits can incorporate into and either suppress/
abolish or enhance, respectively, function of 64*- (although
low levels of function make this conclusion more tenuous),
(h6/h3)h2*-, or (h6/h3)h4*-nAChR, but that effects
are more evident in the presence of chimeric 5/3 subunits.
These studies using the oocyte expression system have been
useful in illuminating the 6*-nAChR structure and function,
and there is the prospect that cell lines containing the same
assemblies could be generated in part to serve the same pur-
pose. With the caveat that 6*-nAChRmay have different sen-
sitivities for agonists or perhaps other types of ligands depend-
ing on whether fully wild-type or one or more gain-of-function
subunits are in the complex, the strategies demonstrated here
to increase function of 6*-nAChR to levels compatible with
drug screening, perhaps using high throughput methods, could
facilitate the development of new drugs selective for 6*-nAChR.
This is of increasing importance given the potentially important
roles for 6*-nAChR in movement and movement disorders,
mood disorders, and drug reinforcement (6, 7, 14–16).
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